ClinicalTrials.gg
Active, not recruitingNCT07284875KaiNETIC-1Updated Oct 6, 2026

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

A Phase 3 interventional study of Ribupatide and Placebo in Obesity and Overweight, sponsored by Kailera. Active, not recruiting at 110 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Kailera · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.

Enrollment
Largest of 16
2,530 · median 142
Started
2025
with 7 others
Phase 3
7 of 16
1 open now
Registered
12th of 16
by date
Lead sponsor
6 of 16
Kailera

Among the 16 studies testing ribupatide in Obesity, this one has the largest enrollment, is one of 8 that started in 2025, is one of 7 in phase 3, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ribupatide in Obesity, or all of them as a file.
02

Study summary

The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Overweight
  • Obesity
  • Ribupatide
  • KAI-9531
  • Glucagon-like Peptide-1
  • GLP-1
  • Glucose-dependent Insulinotropic Peptide
  • GIP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥30 kg/m\^2 or BMI ≥27 kg/m\^2 and previously diagnosed with at least 1 of the following:

    1. hypertension,
    2. dyslipidemia,
    3. obstructive sleep apnea, or
    4. cardiovascular (CV) disease.
  • History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis or history of diabetes mellitus.
  • Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to: tricyclic antidepressants, atypical antipsychotics, mood stabilizers, or phentermine.
  • Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to Screening.
  • Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
  • Uncontrolled hypertension or unstable cardiovascular disease.
  • History of chronic or acute pancreatitis.
  • Known gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.
  • History of suicide attempt.
  • History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.
  • Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonist, GLP-1/glucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,530 participants (actual)

Study arms

  • Experimental
    Ribupatide: Dose 1

    Participants will receive Dose 1 of ribupatide once weekly.

    Drug: Ribupatide

  • Experimental
    Ribupatide: Dose 2

    Participants will receive Dose 2 of ribupatide once weekly.

    Drug: Ribupatide

  • Experimental
    Ribupatide: Dose 3

    Participants will receive Dose 3 of ribupatide once weekly.

    Drug: Ribupatide

  • Experimental
    Ribupatide: Dose 4

    Participants will receive Dose 4 of ribupatide once weekly.

    Drug: Ribupatide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to ribupatide once weekly.

    Drug: Placebo

Interventions

  • SC Injection

    Also known as: KAI-9531

  • DrugPlacebo

    SC Injection

06

What researchers measure

Primary outcomes

  1. Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76

    Time frame: Baseline, Week 76

Secondary outcomes

  1. Dose 1 and 2 versus Placebo: Percent Change From Baseline in Body Weight at Week 76

    Time frame: Baseline, Week 76

  2. Percentage of Participants with ≥5%, ≥10%, ≥15%, ≥20% and ≥25% Reduction in Body Weight

    Time frame: Baseline, Week 76

  3. Change From Baseline in Waist Circumference

    Time frame: Baseline, Week 76

  4. Change From Baseline in Absolute Body Weight

    Time frame: Baseline, Week 76

  5. Change From Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 76

  6. Percent Change From Baseline in Fasting Triglycerides

    Time frame: Baseline, Week 76

  7. Percent Change From Baseline in Fasting High-density Lipoprotein (HDL)-cholesterol

    Time frame: Baseline, Week 76

  8. Percent Change From Baseline in Fasting Non-HDL-cholesterol

    Time frame: Baseline, Week 76

  9. Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

    Time frame: Baseline, Week 76

  10. Participants with Body Mass Index (BMI) ≥35 Kilograms per Square Meter (kg/m^2): Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 76

  11. Percentage of Participants with ≥30% Reduction in Body Weight

    Time frame: Baseline, Week 76

  12. Change From Baseline in BMI

    Time frame: Baseline, Week 76

  13. Change From Baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline, Week 76

  14. Percent Change From Baseline in Total Cholesterol

    Time frame: Baseline, Week 76

  15. Percent Change From Baseline in Low-density Lipoprotein (LDL)-cholesterol

    Time frame: Baseline, Week 76

  16. Percent Change From Baseline in Very Low-density Lipoprotein (VLDL)-cholesterol

    Time frame: Baseline, Week 76

  17. Percent Change From Baseline in Fasting Insulin

    Time frame: Baseline, Week 76

  18. Change From Baseline in Fasting Blood Glucose

    Time frame: Baseline, Week 76

  19. Change From Baseline in Control of Eating Questionnaire (CoEQ) Craving Control Score

    Time frame: Baseline, Week 76

  20. Change From Baseline in CoEQ Positive Mood Score

    Time frame: Baseline, Week 76

  21. Change From Baseline in CoEQ Craving for Sweets Score

    Time frame: Baseline, Week 76

  22. Change From Baseline in CoEQ Craving for Savory Food Score

    Time frame: Baseline, Week 76

  23. Change From Baseline in CoEQ Hunger Score

    Time frame: Baseline, Week 76

  24. Change From Baseline in CoEQ Satiety Score

    Time frame: Baseline, Week 76

  25. Change From Baseline in CoEQ Combined Score

    Time frame: Baseline, Week 76

  26. Change From Baseline in Food Noise Questionnaire (FNQ) Score

    Time frame: Baseline, Week 76

  27. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Week 80

  28. Number of Participants With Anti-drug Antibodies (ADAs)

    Time frame: Up to Week 80

  29. Number of Participants With Neutralizing Antibodies (Nabs)

    Time frame: Up to Week 80

  30. Plasma Concentrations of Ribupatide

    Time frame: Up to Week 76

07

Study locations

110 sites
  • Kailera Clinical Site
    Anniston, Alabama 36207, United States
  • Kailera Clinical Site
    Birmingham, Alabama 35294, United States
  • Kailera Clinical Site
    Cullman, Alabama 35055, United States
  • Kailera Clinical Site
    Sun City, Arizona 85351, United States
  • Kailera Clinical Site
    Escondido, California 92025, United States
  • Kailera Clinical Site
    Toluca Lake, California 91602, United States
  • Kailera Clinical Site
    Aurora, Colorado 80012, United States
  • Kailera Clinical Site
    Bridgeport, Connecticut 06606, United States
  • Kailera Clinical Site
    Jupiter, Florida 33458, United States
  • Kailera Clinical Site
    Lilburn, Georgia 30047, United States
  • Kailera Clinical Site
    Springfield, Illinois 62072, United States
  • Kailera Clinical Site
    Columbia, Maryland 21045, United States
  • Kailera Clinical Site
    Las Vegas, Nevada 89119, United States
  • Kailera Clinical Site
    Rochester, New York 14609, United States
  • Kailera Clinical Site
    Morehead City, North Carolina 28557, United States
  • Kailera Clinical Site
    Chickasha, Oklahoma 73018, United States
  • Kailera Clinical Site
    Mauldin, South Carolina 29662, United States
  • Kailera Clinical Site
    Chattanooga, Tennessee 37405, United States
  • Kailera Clinical Site
    Amarillo, Texas 79124, United States
  • Kailera Clinical Site
    Bellaire, Texas 77401, United States
  • Kailera Clinical Site
    DeSoto, Texas 75115, United States
  • Kailera Clinical Site
    Tomball, Texas 77375, United States
  • Kailera Clinical Site
    Salt Lake City, Utah 84124, United States
  • Kailera Clinical Site
    Danville, Virginia 24541, United States
  • Kailera Clinical Site
    La Plata, Buenos Aires 1900, Argentina
  • Kailera Clinical Site #1
    San Nicolás de los Arroyos, Buenos Aires 2900, Argentina
  • Kailera Clinical Site #2
    San Nicolás de los Arroyos, Buenos Aires 2900, Argentina
  • Kailera Clinical Site #1
    Buenos Aires, Buenos Aires F.D. 1056, Argentina
  • Kailera Clinical Site #2
    Buenos Aires, Buenos Aires F.D. 1056, Argentina
  • Kailera Clinical Site
    Buenos Aires, Buenos Aires F.D. 1060, Argentina
  • Kailera Clinical Site
    Buenos Aires, Buenos Aires F.D. 1120, Argentina
  • Kailera Clinical Site
    Godoy Cruz, Mendoza Province 5501, Argentina
  • Kailera Clinical Site #1
    Rosario, Santa Fe Province 2000, Argentina
  • Kailera Clinical Site #2
    Rosario, Santa Fe Province 2000, Argentina
  • Kailera Clinical Site #3
    Rosario, Santa Fe Province 2000, Argentina
  • Kailera Clinical Site
    CABA, 1061, Argentina
  • Kailera Clinical Site
    Córdoba, 5000, Argentina
  • Kailera Clinical Site
    Charlestown, New South Wales 2290, Australia
  • Kailera Clinical Site
    Sydney, New South Wales 2019, Australia
  • Kailera Clinical Site
    Sydney, New South Wales 2100, Australia
  • Kailera Clinical Site
    Sydney, New South Wales 2228, Australia
  • Kailera Clinical Site
    Wollongong, New South Wales 2500, Australia
  • Kailera Clinical Site
    Sippy Downs, Queensland 4556, Australia
  • Kailera Clinical Site
    Norwood, South Australia 5067, Australia
  • Kailera Clinical Site
    Heidelberg Heights, Victoria 3081, Australia
  • Kailera Clinical Site
    Melbourne, Victoria 3025, Australia
  • Kailera Clinical Site
    Kyustendil, Kyustendil Province 2500, Bulgaria
  • Kailera Clinical Site
    Pazardzhik, 4400, Bulgaria
  • Kailera Clinical Site
    Plovdiv, 4000, Bulgaria
  • Kailera Clinical Site
    Plovdiv, 4020, Bulgaria
  • Kailera Clinical Site #1
    Sofia, 1431, Bulgaria
  • Kailera Clinical Site #2
    Sofia, 1431, Bulgaria
  • Kailera Clinical Site #3
    Sofia, 1431, Bulgaria
  • Kailera Clinical Site
    Sofia, 1510, Bulgaria
  • Kailera Clinical Site
    Sofia, 1527, Bulgaria
  • Kailera Clinical Site
    Varna, 9020, Bulgaria
  • Kailera Clinical Site
    Yambol, 8600, Bulgaria
  • Kailera Clinical Site
    Brandýs nad Labem, Central Bohemia 25001, Czechia
  • Kailera Clinical Site
    Náchod, Hradec Králové Region 54701, Czechia
  • Kailera Clinical Site
    Krnov, Moravian-Silesian Region 79401, Czechia
  • Kailera Clinical Site
    Bohnice, Prague 18100, Czechia
  • Kailera Clinical Site
    Prague, Prague 12808, Czechia
  • Kailera Clinical Site
    Prague, Prague 14059, Czechia
  • Kailera Clinical Site
    Brno, South Moravian 61500, Czechia
  • Kailera Clinical Site
    Hodonín, 69501, Czechia
  • Kailera Clinical Site
    Olomouc, 77900, Czechia
  • Kailera Clinical Site
    Prague, 15000, Czechia
  • Kailera Clinical Site
    Uherské Hradiště, 68601, Czechia
  • Kailera Clinical Site
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Kailera Clinical Site
    Falkensee, Brandenburg 14612, Germany
  • Kailera Clinical Site
    Cologne, North Rhine-Westphalia 51069, Germany
  • Kailera Clinical Site
    Essen, North Rhine-Westphalia 45355, Germany
  • Kailera Clinical Site
    Dresden, Saxony 01069, Germany
  • Kailera Clinical Site
    Leipzig, Saxony 04107, Germany
  • Kailera Clinical Site
    Oldenburg in Holstein, Schleswig-Holstein 23758, Germany
  • Kailera Clinical Site
    Hamburg, 22415, Germany
  • Kailera Clinical Site
    Hamburg, 22607, Germany
  • Kailera Clinical Site
    Schwerin, 19055, Germany
  • Kailera Clinical Site
    Grafton, Auckland 1010, New Zealand
  • Kailera Clinical Site
    Silverdale, Auckland 0932, New Zealand
  • Kailera Clinical Site
    Hamilton, Waikato Region 3200, New Zealand
  • Kailera Clinical Site
    Auckland, 0610, New Zealand
  • Kailera Clinical Site
    Nelson, 7011, New Zealand
  • Kailera Clinical Site
    Poznan, Greater Poland Voivodeship 60-589, Poland
  • Kailera Clinical Site
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
  • Kailera Clinical Site
    Krakow, Lesser Poland Voivodeship 30-363, Poland
  • Kailera Clinical Site
    Siedlce, Masovian Voivodeship 08-110, Poland
  • Kailera Clinical Site
    Warsaw, Masovian Voivodeship 00-872, Poland
  • Kailera Clinical Site
    Skierniewice, 96-100, Poland
  • Kailera Clinical Site
    Zamość, 22-400, Poland
  • Kailera Clinical Site
    Ferrol, A Coruna 15402, Spain
  • Kailera Clinical Site
    Seville, Andalusia 41010, Spain
  • Kailera Clinical Site
    Villamartín, Cadiz 11650, Spain
  • Kailera Clinical Site
    Barcelona, Catalonia 08035, Spain
  • Kailera Clinical Site
    Oviedo, Principality of Asturias 33011, Spain
  • Kailera Clinical Site
    Castilleja de la Cuesta, Sevilla 41950, Spain
  • Kailera Clinical Site
    Barcelona, 08023, Spain
  • Kailera Clinical Site
    Madrid, 28003, Spain
  • Kailera Clinical Site
    Valencia, 46014, Spain
  • Kailera Clinical Site
    Soham, Cambridgeshire CB7 5JD, United Kingdom

Showing the first 100 of 110 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Feb 2028, 26 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 26 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 16, 2025
StartActual
Dec 18, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Mar 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Sites
10 sites added, 4 sites removed
Show 10 added (7 Argentina, 3 Bulgaria)
  • Kailera Clinical Site #1 · San Nicolás de los Arroyos, Argentina
  • Kailera Clinical Site #2 · San Nicolás de los Arroyos, Argentina
  • Kailera Clinical Site #1 · Buenos Aires, Argentina
  • Kailera Clinical Site #2 · Buenos Aires, Argentina
  • Kailera Clinical Site #1 · Rosario, Argentina
  • Kailera Clinical Site #2 · Rosario, Argentina
  • Kailera Clinical Site #3 · Rosario, Argentina
  • Kailera Clinical Site #1 · Sofia, Bulgaria
  • Kailera Clinical Site #2 · Sofia, Bulgaria
  • Kailera Clinical Site #3 · Sofia, Bulgaria
Show 4 removed
  • Kailera Clinical Site · San Nicolás de los Arroyos, Argentina
  • Kailera Clinical Site · Buenos Aires, Argentina
  • Kailera Clinical Site · Rosario, Argentina
  • Kailera Clinical Site · Sofia, Bulgaria
Oct 6, 2026
Enrollment
2340 (estimated)→2530 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    10 sites added, 4 sites removed
    Show 10 added (7 Argentina, 3 Bulgaria)
    • Kailera Clinical Site #1 · San Nicolás de los Arroyos, Argentina
    • Kailera Clinical Site #2 · San Nicolás de los Arroyos, Argentina
    • Kailera Clinical Site #1 · Buenos Aires, Argentina
    • Kailera Clinical Site #2 · Buenos Aires, Argentina
    • Kailera Clinical Site #1 · Rosario, Argentina
    • Kailera Clinical Site #2 · Rosario, Argentina
    • Kailera Clinical Site #3 · Rosario, Argentina
    • Kailera Clinical Site #1 · Sofia, Bulgaria
    • Kailera Clinical Site #2 · Sofia, Bulgaria
    • Kailera Clinical Site #3 · Sofia, Bulgaria
    Show 4 removed
    • Kailera Clinical Site · San Nicolás de los Arroyos, Argentina
    • Kailera Clinical Site · Buenos Aires, Argentina
    • Kailera Clinical Site · Rosario, Argentina
    • Kailera Clinical Site · Sofia, Bulgaria
    Enrollment 2340 (estimated)→2530 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284875
Lead sponsor
Kailera
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Dec 18, 2025
Primary completion
Feb 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Medical Director
study director · Kailera Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion